首页 > 最新文献

Reumatologia Clinica最新文献

英文 中文
Infecciones graves en vasculitis necrosantes sistémicas 全身坏死性血管炎的严重感染
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.003
Claudia Pena, Ana Carolina Costi, Lucila García, Mercedes García

Infections in patients with systemic vasculitis represent one of the main causes of mortality. Corticosteroid use, immunosuppressive therapy, age, associated organic involvement and dialysis dependence are risk factors of infection.

Objectives

To determine the prevalence of severe infection and associated factors in patients diagnosed with ANCA-associated vasculitis and polyarteritis nodosa (PAN).

Methods

Retrospective study was conduced in a single rheumatology center (2000-2018). We included patients diagnosed with ANCA-associated vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis and PAN. Serious infectious events requiring hospitalization or prolonged antibiotic/antiviral treatment, recurrent infection of herpes zoster virus or opportunistic infections were evaluated. Sites of infection, isolated microorganisms and mortality related were analyzed.

Results

A total of 105 patients were analyzed, follow-up time median 18 months, 58.7% were women and median age was 52 years. Types of vasculitis: 41.9% microscopic polyangiitis, 16.2% eosinophilic granulomatosis with polyangiitis, 40% granulomatosis with polyangiitis, 1.9% PAN. Constitutional, pulmonary, renal and otorhinolaryngology manifestations were the most frequent.

The prevalence of infection

was 34,2%, with a median of 3 months from diagnosis of vasculitis to the infectious event. Low respiratory tract (42.8%), sepsis (31.4%), and urinary tract (14.3%) were the most common sites of infections. Bacterial etiology was the most prevalent (67.7%). Mortality at the first event was 14.3% and a 72.2% of patients were in the induction phase of treatment.

Infectious events were significantly associated with age > 65 years (P = 0.030), presence of lung (P = 0.016) and renal involvement (P = 0.001), BVASv3 > 15 and mortality (P = 0.0002).

Conclusions

The prevalence of infection was 34.2%. Lower airway infections, septicemia and urinary tract infections were the most prevalent. Infections were associated with renal and pulmonary involvement, age older than 65 years and score BVAS >15. Severe infections were associated with mortality, especially in elderly patients.

全身性血管炎患者感染是导致死亡的主要原因之一。方法 在一个风湿病学中心开展了一项回顾性研究(2000-2018 年)。我们纳入了被诊断为ANCA相关性血管炎(肉芽肿伴多血管炎、嗜酸性肉芽肿伴多血管炎、显微镜下多血管炎和结节性多动脉炎)的患者。对需要住院治疗或长期抗生素/抗病毒治疗的严重感染事件、带状疱疹病毒反复感染或机会性感染进行了评估。结果 共分析了 105 名患者,随访时间中位数为 18 个月,58.7% 为女性,年龄中位数为 52 岁。血管炎类型:41.9%为显微镜下多血管炎,16.2%为嗜酸性粒细胞肉芽肿伴多血管炎,40%为肉芽肿伴多血管炎,1.9%为PAN。感染率为 34.2%,从确诊血管炎到发生感染事件的中位时间为 3 个月。低呼吸道(42.8%)、败血症(31.4%)和泌尿道(14.3%)是最常见的感染部位。细菌是最常见的病因(67.7%)。感染事件与年龄(65 岁)(P = 0.030)、肺部(P = 0.016)和肾脏受累(P = 0.001)、BVASv3(15)和死亡率(P = 0.0002)显著相关。下呼吸道感染、脓毒血症和尿路感染最为常见。感染与肾脏和肺部受累、65 岁以上和 BVAS 评分 15 分有关。严重感染与死亡率有关,尤其是在老年患者中。
{"title":"Infecciones graves en vasculitis necrosantes sistémicas","authors":"Claudia Pena,&nbsp;Ana Carolina Costi,&nbsp;Lucila García,&nbsp;Mercedes García","doi":"10.1016/j.reuma.2024.01.003","DOIUrl":"10.1016/j.reuma.2024.01.003","url":null,"abstract":"<div><p>Infections in patients with systemic vasculitis represent one of the main causes of mortality. Corticosteroid use, immunosuppressive therapy, age, associated organic involvement and dialysis dependence are risk factors of infection.</p></div><div><h3>Objectives</h3><p>To determine the prevalence of severe infection and associated factors in patients diagnosed with ANCA-associated vasculitis and polyarteritis nodosa (PAN).</p></div><div><h3>Methods</h3><p>Retrospective study was conduced in a single rheumatology center (2000-2018). We included patients diagnosed with ANCA-associated vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis and PAN. Serious infectious events requiring hospitalization or prolonged antibiotic/antiviral treatment, recurrent infection of herpes zoster virus or opportunistic infections were evaluated. Sites of infection, isolated microorganisms and mortality related were analyzed.</p></div><div><h3>Results</h3><p>A total of 105 patients were analyzed, follow-up time median 18 months, 58.7% were women and median age was 52 years. Types of vasculitis: 41.9% microscopic polyangiitis, 16.2% eosinophilic granulomatosis with polyangiitis, 40% granulomatosis with polyangiitis, 1.9% PAN. Constitutional, pulmonary, renal and otorhinolaryngology manifestations were the most frequent.</p></div><div><h3>The prevalence of infection</h3><p>was 34,2%, with a median of 3 months from diagnosis of vasculitis to the infectious event. Low respiratory tract (42.8%), sepsis (31.4%), and urinary tract (14.3%) were the most common sites of infections. Bacterial etiology was the most prevalent (67.7%). Mortality at the first event was 14.3% and a 72.2% of patients were in the induction phase of treatment.</p><p>Infectious events were significantly associated with age<!--> <!-->&gt; 65 years (<em>P</em> <!-->=<!--> <!-->0.030), presence of lung (<em>P</em> <!-->=<!--> <!-->0.016) and renal involvement (<em>P</em> <!-->=<!--> <!-->0.001), BVASv3<!--> <!-->&gt; 15 and mortality (<em>P</em> <!-->=<!--> <!-->0.0002).</p></div><div><h3>Conclusions</h3><p>The prevalence of infection was 34.2%. Lower airway infections, septicemia and urinary tract infections were the most prevalent. Infections were associated with renal and pulmonary involvement, age older than 65 years and score BVAS<!--> <!-->&gt;15. Severe infections were associated with mortality, especially in elderly patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140469368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk 系统性自身免疫疾病患者的心血管疾病:自我感觉风险与实际风险之间的关系
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.002
Cristiana Sieiro Santos , Maria Miguel Oliveira , Paulo Ney Solari , Pedro Mateus , Maria José Santos , Hector Corominas , Carolina Álvarez Castro , Elvira Díez Álvarez

Introduction

Autoimmune diseases are known to be associated with an elevated risk of cardiovascular diseases; however, there exists a lack of awareness regarding this increased risk among patients.

Objective

This study aimed to assess the prevalence of cardiovascular risk factors and events in various systemic autoimmune diseases, including Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's syndrome (SS), matched by age, sex, and disease duration. Additionally, the study aimed to evaluate the perceived and actual risks of cardiovascular disease among patients.

Methods

A cross-sectional self-reported survey on the patient's perspective of cardiovascular risk was conducted between January and June 2023. Sociodemographic and clinical data, including disease activity, were collected through medical records and questionnaires. Traditional cardiovascular risk factors and events were assessed, alongside the perceived cardiovascular risk. The SCORE calculation and Charlson Comorbidity Index (CCI) were employed for cardiovascular risk assessment.

Results

Survey responses from 180 patients (45 patients each with SSc, SLE, RA, and SS) with systemic autoimmune diseases revealed that 20% perceived a low risk, 23% perceived neither lower nor higher, and 56% perceived a higher risk of developing cardiovascular diseases in the next ten years. Only 45% agreed that their autoimmune disease could increase the risk of a heart attack, even in the absence of other risk factors, and 46.7% were unaware that NSAIDs pose a cardiovascular risk. An association between cardiovascular risk measured by SCORE, comorbidities, and risk perception was observed in RA, SSc, and SS patients, with no association found in SLE patients (p = 0.27). Except for SS patients (p = 0.02), no association between CCI and disease activity level was found. Regarding the influence of age, working status, and education in CVD risk perception, an association between CVD risk perception and age was observed (p = 0.01), with patients over 40 years exhibiting a higher perception of CVD risk. No differences were found regarding working status (p = 0.19) nor education level (p = 0.06).

Conclusions

Patients with SS, RA, and SSc displayed a heightened perception of cardiovascular risk, correlating with their actual risk and preexisting comorbidities. However, patients exhibited unawareness of certain cardiovascular risk behaviors. This underscores the need for tailored education programs on cardiovascular risk for autoimmune disease patients, to be implemented at the time of diagnosis and during follow-up in outpatient clinics.

导言:众所周知,自身免疫性疾病与心血管疾病风险升高有关;然而,患者对这种风险升高缺乏认识。本研究旨在评估各种系统性自身免疫性疾病(包括系统性硬化症(SSc)、系统性红斑狼疮(SLE)、类风湿性关节炎(RA)和斯约格伦综合征(SS))中心血管风险因素和事件的发生率,并根据年龄、性别和病程进行匹配。此外,该研究还旨在评估患者感知到的和实际存在的心血管疾病风险。方法在 2023 年 1 月至 6 月期间进行了一项横断面自我报告调查,内容涉及患者对心血管疾病风险的看法。通过病历和问卷收集了社会人口学和临床数据,包括疾病活动性。在评估心血管风险的同时,还评估了传统的心血管风险因素和事件。结果对 180 名系统性自身免疫疾病患者(系统性红斑狼疮、系统性红斑狼疮、RA 和 SS 患者各 45 名)进行的调查显示,20% 的患者认为未来 10 年罹患心血管疾病的风险较低,23% 的患者认为风险既不低也不高,56% 的患者认为风险较高。只有 45% 的人同意,即使没有其他风险因素,他们的自身免疫性疾病也会增加心脏病发作的风险,46.7% 的人不知道非甾体抗炎药会带来心血管风险。在 RA、SSc 和 SS 患者中,通过 SCORE 测量的心血管风险、合并症和风险认知之间存在关联,而在系统性红斑狼疮患者中未发现关联(p = 0.27)。除 SS 患者(p = 0.02)外,CCI 与疾病活动程度之间没有关联。关于年龄、工作状况和教育程度对心血管疾病风险认知的影响,观察到心血管疾病风险认知与年龄之间存在关联(p = 0.01),40 岁以上的患者对心血管疾病风险的认知度更高。结论 SS、RA 和 SSc 患者对心血管风险的认知度较高,这与他们的实际风险和既往合并症相关。然而,患者对某些心血管风险行为并不了解。这强调了为自身免疫性疾病患者量身定制心血管风险教育计划的必要性,该计划应在诊断时和门诊随访期间实施。
{"title":"Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk","authors":"Cristiana Sieiro Santos ,&nbsp;Maria Miguel Oliveira ,&nbsp;Paulo Ney Solari ,&nbsp;Pedro Mateus ,&nbsp;Maria José Santos ,&nbsp;Hector Corominas ,&nbsp;Carolina Álvarez Castro ,&nbsp;Elvira Díez Álvarez","doi":"10.1016/j.reuma.2024.01.002","DOIUrl":"10.1016/j.reuma.2024.01.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Autoimmune diseases are known to be associated with an elevated risk of cardiovascular diseases; however, there exists a lack of awareness regarding this increased risk among patients.</p></div><div><h3>Objective</h3><p>This study aimed to assess the prevalence of cardiovascular risk factors and events in various systemic autoimmune diseases, including Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's syndrome (SS), matched by age, sex, and disease duration. Additionally, the study aimed to evaluate the perceived and actual risks of cardiovascular disease among patients.</p></div><div><h3>Methods</h3><p>A cross-sectional self-reported survey on the patient's perspective of cardiovascular risk was conducted between January and June 2023. Sociodemographic and clinical data, including disease activity, were collected through medical records and questionnaires. Traditional cardiovascular risk factors and events were assessed, alongside the perceived cardiovascular risk. The SCORE calculation and Charlson Comorbidity Index (CCI) were employed for cardiovascular risk assessment.</p></div><div><h3>Results</h3><p>Survey responses from 180 patients (45 patients each with SSc, SLE, RA, and SS) with systemic autoimmune diseases revealed that 20% perceived a low risk, 23% perceived neither lower nor higher, and 56% perceived a higher risk of developing cardiovascular diseases in the next ten years. Only 45% agreed that their autoimmune disease could increase the risk of a heart attack, even in the absence of other risk factors, and 46.7% were unaware that NSAIDs pose a cardiovascular risk. An association between cardiovascular risk measured by SCORE, comorbidities, and risk perception was observed in RA, SSc, and SS patients, with no association found in SLE patients (<em>p</em> <!-->=<!--> <!-->0.27). Except for SS patients (<em>p</em> <!-->=<!--> <!-->0.02), no association between CCI and disease activity level was found. Regarding the influence of age, working status, and education in CVD risk perception, an association between CVD risk perception and age was observed (<em>p</em> <!-->=<!--> <!-->0.01), with patients over 40 years exhibiting a higher perception of CVD risk. No differences were found regarding working status (<em>p</em> <!-->=<!--> <!-->0.19) nor education level (<em>p</em> <!-->=<!--> <!-->0.06).</p></div><div><h3>Conclusions</h3><p>Patients with SS, RA, and SSc displayed a heightened perception of cardiovascular risk, correlating with their actual risk and preexisting comorbidities. However, patients exhibited unawareness of certain cardiovascular risk behaviors. This underscores the need for tailored education programs on cardiovascular risk for autoimmune disease patients, to be implemented at the time of diagnosis and during follow-up in outpatient clinics.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comunicaciones orales 口头交流
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00059-7
{"title":"Comunicaciones orales","authors":"","doi":"10.1016/S1699-258X(24)00059-7","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00059-7","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pósteres: P1-P99 海报:P1-P99
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00061-5
{"title":"Pósteres: P1-P99","authors":"","doi":"10.1016/S1699-258X(24)00061-5","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00061-5","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pósteres: P100-P199 海报:P100-P199
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00062-7
{"title":"Pósteres: P100-P199","authors":"","doi":"10.1016/S1699-258X(24)00062-7","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00062-7","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pósteres: P400-P465 海报:P400-P465
IF 1.5 Q3 Medicine Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00065-2
{"title":"Pósteres: P400-P465","authors":"","doi":"10.1016/S1699-258X(24)00065-2","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00065-2","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytokine storm in Chikungunya: Can we call it multisystem inflammatory syndrome associated with Chikungunya? 基孔肯雅病毒的细胞因子风暴:我们可以将其称为与基孔肯雅病相关的多系统炎症综合征吗?
IF 1.5 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.reuma.2023.10.003
Zoilo Morel , Tamara Martínez , Fernando Galeano , Judith Coronel , Lorena Quintero , Rolando Jimenez , Jorge Ayala , Sara Amarilla , Dolores Lovera , Celia Martínez de Cuellar

Paraguay is currently facing a new outbreak of Chikungunya virus. This report summarizes two severe cases of Chikungunya (CHIKV) infection, confirmed by real-time reverse transcription polymerase chain reaction. We present the cases of patients with acute CHIKV infection and multisystem involvement, with fever, rash, abdominal pain, vomiting, myocarditis, and coronary artery anomalies, very similar to the cases described in MIS-C related to SARS-CoV-2 during the COVID-19 Pandemic. Both patients received IVIG and methylprednisolone, with good clinical response. In this setting of cytokine storm in Chikungunya, can we call it “Multisystem inflammatory syndrome associated with Chikungunya”?.

巴拉圭目前正面临基孔肯雅病毒的新一轮爆发。本报告概述了经实时反转录聚合酶链反应证实的两例基孔肯雅病毒(CHIKV)严重感染病例。我们报告的病例是基孔肯雅病毒急性感染和多系统受累的患者,伴有发热、皮疹、腹痛、呕吐、心肌炎和冠状动脉异常,与 COVID-19 大流行期间与 SARS-CoV-2 相关的 MIS-C 中描述的病例非常相似。两名患者均接受了静脉注射免疫球蛋白和甲基强的松龙治疗,临床反应良好。在基孔肯雅病毒引起细胞因子风暴的情况下,我们是否可以称之为 "与基孔肯雅病毒相关的多系统炎症综合征"?
{"title":"Cytokine storm in Chikungunya: Can we call it multisystem inflammatory syndrome associated with Chikungunya?","authors":"Zoilo Morel ,&nbsp;Tamara Martínez ,&nbsp;Fernando Galeano ,&nbsp;Judith Coronel ,&nbsp;Lorena Quintero ,&nbsp;Rolando Jimenez ,&nbsp;Jorge Ayala ,&nbsp;Sara Amarilla ,&nbsp;Dolores Lovera ,&nbsp;Celia Martínez de Cuellar","doi":"10.1016/j.reuma.2023.10.003","DOIUrl":"10.1016/j.reuma.2023.10.003","url":null,"abstract":"<div><p>Paraguay is currently facing a new outbreak of Chikungunya virus. This report summarizes two severe cases of Chikungunya (CHIKV) infection, confirmed by real-time reverse transcription polymerase chain reaction. We present the cases of patients with acute CHIKV infection and multisystem involvement, with fever, rash, abdominal pain, vomiting, myocarditis, and coronary artery anomalies, very similar to the cases described in MIS-C related to SARS-CoV-2 during the COVID-19 Pandemic. Both patients received IVIG and methylprednisolone, with good clinical response. In this setting of cytokine storm in Chikungunya, can we call it “Multisystem inflammatory syndrome associated with Chikungunya”?.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139293529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does sacroiliitis is a mandatory criterion for enthesitis-related arthritis diagnosis? 骶髂关节炎是诊断粘连性关节炎的硬性标准吗?
IF 1.5 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.reuma.2023.12.005
Hanene Lassoued Ferjani , Lobna Kharrat , Dorra Ben Nessib , Dhia Kaffel , Kaouther Maatallah , Wafa Hamdi

Introduction and objectives

Magnetic resonance imaging (MRI) sensitivity and specificity seem to be less studied in enthesitis-related arthritis (ERA).

We aimed to determine the ability of sacroiliac MRI to diagnose ERA patients.

Materials and methods

We conducted a retrospective study including 44 patients with juvenile idiopathic arthritis (JIA). Each patient had a sacroiliac joint MRI. We divided patients into two groups: G1 patients with ERA and G2 patients with non-ERA subtype.

Results

ERA was noted in 61% of the cases. Sacroiliac joints were painful in 15 patients (34%). MRI was normal in 25 patients (57%) (G1:11 versus G2:14) and showed bone marrow edema in the sacroiliac joints in 19 patients (34%) (G1 = 16 versus G2 = 3, p = 0.005).

Sacroiliac joints MRI's sensitivity and specificity in the ERA diagnosis were 61.54% and 82.35%, respectively. Positive and negative predictive values were 84.21% and 58.33%, respectively. Furthermore, sacroiliac joint pain in the clinical examination was able to predict sacroiliac bone edema in MRI with an odds ratio of 6.8 (95% CI 1.68–28.09; p = 0.006).

Conclusion

Our study showed that sacroiliac joint MRI has good specificity and positive predictive value in the diagnosis of ERA patients among JIA patients. This underlines the usefulness of sacroiliac joint MRI in the early diagnosis of ERA patients.

导言和目标磁共振成像(MRI)的敏感性和特异性在关节炎相关性关节炎(ERA)中的研究似乎较少。我们旨在确定骶髂关节 MRI 诊断ERA 患者的能力。每位患者都进行了骶髂关节磁共振成像检查。我们将患者分为两组:结果 61%的病例发现ERA。15例患者(34%)骶髂关节疼痛。25 名患者(57%)(G1:11 对 G2:14)磁共振成像正常,19 名患者(34%)(G1 = 16 对 G2 = 3,P = 0.005)骶髂关节磁共振成像在 ERA 诊断中的敏感性和特异性分别为 61.54% 和 82.35%。骶髂关节磁共振成像对 ERA 诊断的敏感性和特异性分别为 61.54% 和 82.35%,阳性预测值和阴性预测值分别为 84.21% 和 58.33%。此外,临床检查中的骶髂关节疼痛能够预测 MRI 中的骶髂骨水肿,其几率比为 6.8 (95% CI 1.68-28.09; p = 0.006)。这凸显了骶髂关节磁共振成像在ERA患者早期诊断中的作用。
{"title":"Does sacroiliitis is a mandatory criterion for enthesitis-related arthritis diagnosis?","authors":"Hanene Lassoued Ferjani ,&nbsp;Lobna Kharrat ,&nbsp;Dorra Ben Nessib ,&nbsp;Dhia Kaffel ,&nbsp;Kaouther Maatallah ,&nbsp;Wafa Hamdi","doi":"10.1016/j.reuma.2023.12.005","DOIUrl":"10.1016/j.reuma.2023.12.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Magnetic resonance imaging (MRI) sensitivity and specificity seem to be less studied in enthesitis-related arthritis (ERA).</p><p>We aimed to determine the ability of sacroiliac MRI to diagnose ERA patients.</p></div><div><h3>Materials and methods</h3><p>We conducted a retrospective study including 44 patients with juvenile idiopathic arthritis (JIA). Each patient had a sacroiliac joint MRI. We divided patients into two groups: G1 patients with ERA and G2 patients with non-ERA subtype.</p></div><div><h3>Results</h3><p>ERA was noted in 61% of the cases. Sacroiliac joints were painful in 15 patients (34%). MRI was normal in 25 patients (57%) (G1:11 versus G2:14) and showed bone marrow edema in the sacroiliac joints in 19 patients (34%) (G1<!--> <!-->=<!--> <!-->16 versus G2<!--> <!-->=<!--> <!-->3, <em>p</em> <!-->=<!--> <!-->0.005).</p><p>Sacroiliac joints MRI's sensitivity and specificity in the ERA diagnosis were 61.54% and 82.35%, respectively. Positive and negative predictive values were 84.21% and 58.33%, respectively. Furthermore, sacroiliac joint pain in the clinical examination was able to predict sacroiliac bone edema in MRI with an odds ratio of 6.8 (95% CI 1.68–28.09; <em>p</em> <!-->=<!--> <!-->0.006).</p></div><div><h3>Conclusion</h3><p>Our study showed that sacroiliac joint MRI has good specificity and positive predictive value in the diagnosis of ERA patients among JIA patients. This underlines the usefulness of sacroiliac joint MRI in the early diagnosis of ERA patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139538619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La p.(Tyr135His), una nueva variante asociada a la fiebre mediterránea familiar p.(Tyr135His),一个与家族性地中海热相关的新变体
IF 1.5 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.reuma.2023.09.010
Francisco José Nicolás-Sánchez , Lluis Eleuteri Pons I Ferré , Francesc Josep Nicolás-Sarrat , Alberto González Barranquero
{"title":"La p.(Tyr135His), una nueva variante asociada a la fiebre mediterránea familiar","authors":"Francisco José Nicolás-Sánchez ,&nbsp;Lluis Eleuteri Pons I Ferré ,&nbsp;Francesc Josep Nicolás-Sarrat ,&nbsp;Alberto González Barranquero","doi":"10.1016/j.reuma.2023.09.010","DOIUrl":"10.1016/j.reuma.2023.09.010","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135850287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recomendaciones SER sobre el tratamiento del síndrome de Behçet refractario 关于治疗难治性白塞氏综合征的 SER 建议
IF 1.5 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.reuma.2023.12.001
Clara Moriano Morales , Jenaro Graña Gil , Noé Brito García , José Luis Martín Varillas , Vanesa Calvo del Río , Patricia Moya Alvarado , Francisco Javier Narváez García , Gerard Espinosa , Petra Díaz del Campo Fontecha , Mercedes Guerra Rodríguez , José Mateo Arranz , Manuela López Gómez , Félix Manuel Francisco Hernández , M. Mar Trujillo , Raquel dos Santos Sobrín , Juan Ignacio Martín Sánchez , Jesús Maese Manzano , Julio Suárez Cuba

Objective

To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (difficult to treat, severe resistant, severe relapse) to conventional treatment.

Methods

A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format –patient, intervention, comparison and outcome–. Systematic reviews of the evidence were conducted; the quality of the evidence was evaluated following the methodology of the international working group Grading of Recommendations, Assessment, Development, and Evaluation. After that, the multidisciplinary panel formulated the specific recommendations.

Results

Four PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with Behçet's syndrome with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus.

Conclusions

The treatment of most severe clinical manifestations of Behçet's syndrome lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.

目标在现有证据和专家共识的基础上,为常规治疗难治性白塞氏综合征(难治、严重耐药、严重复发)患者的治疗管理制定多学科建议。这些问题以 PICO 格式(患者、干预、比较和结果)重新表述。对证据进行了系统回顾,并按照国际工作组的建议、评估、发展和评价分级方法对证据质量进行了评估。然后,多学科专家小组制定了具体建议。结果选择了四个 PICO 问题,涉及对传统疗法难治的临床表现为粘膜和/或关节、血管、神经实质和胃肠表型的贝赫切特综合征患者进行系统药物治疗的有效性和安全性。结论贝赫切特综合征最严重临床表现的治疗缺乏可靠的科学证据,此外,也没有针对难治性疾病患者的具体推荐文件。为了满足这一需求,我们在此提交了西班牙风湿病学会针对此类患者治疗的首份官方建议。这些建议旨在协助临床决策、统一治疗方案并减少此类患者治疗过程中的变异性。
{"title":"Recomendaciones SER sobre el tratamiento del síndrome de Behçet refractario","authors":"Clara Moriano Morales ,&nbsp;Jenaro Graña Gil ,&nbsp;Noé Brito García ,&nbsp;José Luis Martín Varillas ,&nbsp;Vanesa Calvo del Río ,&nbsp;Patricia Moya Alvarado ,&nbsp;Francisco Javier Narváez García ,&nbsp;Gerard Espinosa ,&nbsp;Petra Díaz del Campo Fontecha ,&nbsp;Mercedes Guerra Rodríguez ,&nbsp;José Mateo Arranz ,&nbsp;Manuela López Gómez ,&nbsp;Félix Manuel Francisco Hernández ,&nbsp;M. Mar Trujillo ,&nbsp;Raquel dos Santos Sobrín ,&nbsp;Juan Ignacio Martín Sánchez ,&nbsp;Jesús Maese Manzano ,&nbsp;Julio Suárez Cuba","doi":"10.1016/j.reuma.2023.12.001","DOIUrl":"10.1016/j.reuma.2023.12.001","url":null,"abstract":"<div><h3>Objective</h3><p>To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (difficult to treat, severe resistant, severe relapse) to conventional treatment.</p></div><div><h3>Methods</h3><p>A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format –patient, intervention, comparison and outcome–. Systematic reviews of the evidence were conducted; the quality of the evidence was evaluated following the methodology of the international working group <em>Grading of Recommendations, Assessment, Development, and Evaluation</em>. After that, the multidisciplinary panel formulated the specific recommendations.</p></div><div><h3>Results</h3><p>Four PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with Behçet's syndrome with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus.</p></div><div><h3>Conclusions</h3><p>The treatment of most severe clinical manifestations of Behçet's syndrome lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139395267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia Clinica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1